Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors
Breast cancer is a leading cause of death among women globally. Estrogen receptor (ER)-positive breast cancers account for ∼70 % of breast cancer diagnoses worldwide. Endocrine therapy is the primary treatment approach for ER-positive breast cancer. In the United States, the Food and Drug Administra...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2026-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Assuntos: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S2468294226000456 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|